Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9034)	9/2/2003 4:37:20 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

Peter I believe that the authors are suggesting that pharmas should license early and pay more. Such a strategy would be do the benefit of both the pharma and the biotech. (In addition it might keep more biotech off the ambition to start to market their drugs themselves). Roche is a very good example of a pharmaceutical company who already seems to have adopted this policy. The terms in their agreements with Isotechnika and our Swedish Medivir were both surprisingly early and much richer than what normally would be expected from such deals. Erik